In 2004-07 most Medicare-eligible men were getting radiation therapy for first-line treatment of prostate cancer

In a second article in the new journal JAMA Oncology, researchers at the University of California Los Angeles suggest that 58 percent of all relatively recent treatment for prostate cancer was being given by radiation therapy of some type, and that indolent prostate cancer was being significantly over-treated. … READ MORE …

Is active surveillance appropriate for men with favorable intermediate-risk prostate cancer?

In a paper in the first issue of the new journal JAMA Oncology, a group of US-based researchers argue that data from a series of > 5,000 patients treated with first-line brachytherapy suggest that men with favorable intermediate-risk prostate cancer are actually good candidates for active surveillance. … READ MORE …

James Mohler talks prostate cancer on CureTalk

On Tuesday this week, Dr. James L. Mohler of Roswell Park Cancer Institute participated in an hour-long discussion on key issues related to the diagnosis and management of early stage prostate cancer. … READ MORE …

Ageism in prostate cancer treatment

We’ve all heard the age-related treatment recommendations of doctors. … READ MORE …

Consensus statement on pathologic factors and active surveillance

As previously mentioned earlier this week, a long statement that deals with the role of the pathologist in determining the suitability of patients for enrollment into active surveillance management protocols has been issued and endorsed by a number of organizations. … READ MORE …

New US national prostate cancer data classified by NCCN risk category

Prior to 2013, when the National Cancer Institute released accumulated, de-identified, prostate cancer-specific patient data from the national SEER cancer registry, those data only included the post-surgical, pathological Gleason scores and not the biopsy Gleason scores. … READ MORE …

First 6 months of first off-therapy cycle may determine effectiveness of intermittent ADT

A new paper in Clinical Genitourinary Cancer provides some intriguing information about determining the likelihood of good and less good long-term responses to intermittent androgen deprivation therapy (ADT) among men with non-metastatic prostate cancer. Be warned: This is going to be a long post with a lot of data. … READ MORE …

Follow

Get every new post delivered to your Inbox.

Join 1,241 other followers